Quick links to important sections

Skinoren

Selected form

Cream

Method of action:

Treatment option:

Top 20 medicines with the same components:

Dosage (Posology) and method of administration

Method of administration

Cutaneous use

Dosage regimen

Skinoren Cream should be applied to the affected areas of skin twice daily (mornings and evenings), and rubbed in gently. As a guide 2.5 cm (approx. 0.5 g) of cream is sufficient for the entire facial area. If other areas of acne, in addition to the face require treatment, for example the chest and back, the amount of cream should be adjusted accordingly.

Patients with sensitive skin should be advised to use Skinoren only once a day (in the evening) for the first week of treatment and then proceed to twice daily applications.

Before Skinoren Cream is applied, the skin should be thoroughly cleaned with plain water and dried. A mild skin-cleansing agent may be used.

The duration of use of Skinoren Cream can vary from patient to patient and also depends on the severity of the acne.).

It is important to continue to use Skinoren Cream regularly over the entire period of treatment. However, in the event of intolerable skin irritation , the amount of cream per application should be reduced or the frequency of use of Skinoren Cream should be reduced to once a day until the irritation ceases. If required, treatment might have to be temporarily interrupted for a few days.

Additional information on special populations

Paediatric population

Use in adolescents (12 - 18 years of age): dose adjustment is not required when Skinoren Cream is administered to adolescents aged 12 - 18 years.

The safety and efficacy of Skinoren Cream in children below the age of 12 years have not been established.

Geriatric patients

No targeted studies have been performed in patients aged 65 and over.

Patients with hepatic impairment

No targeted studies have been performed in patients with hepatic impairment.

Patients with renal impairment

No targeted studies have been performed in patients with renal impairment.

Undesirable effects

From clinical studies and post-marketing surveillance, the most frequently observed side-effects included application site burning, application site pruritus and application site erythema.

Frequencies of side-effects observed in clinical studies and post-marketing surveillance and given in the table below are defined according to the MedDRA frequency convention:

Very common (>1/10), Common (>1/100 to <1/10), Uncommon (>1/1,000 to <1/100), Rare (>1/10,000 to <1/1,000), Very rare (<1/10,000), Not known (cannot be estimated from the available data).

System Organ Class	Very Common	Common	Uncommon	Rare	Not known¹
Skin and subcutaneous tissue disorders			seborrhoea, acne, skin depigmentation	cheilitis	Urticaria rash
General disorders and administration site conditions	application site burning, application site pruritus, application site erythema	application site exfoliation, application site pain, application site dryness, application site discolouration, application site irritation	application site paraesthesia, application site dermatitis, application site discomfort, application site oedema	application site vesicles, application site eczema, application site warmth, application site ulcer,
Immune system disorders				drug hypersensitivity, worsening of asthma	angioedema², dermatitis contact² , eye swelling², swelling face²

¹ These additional adverse reactions have been reported during post-approval use of Skinoren cream (frequency unknown).

² may occur with hypersensitivity

Generally, local skin irritation regresses in the course of treatment.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

Overdose

No known cases of azelaic acid overdosage resulting from topical administration of Skinoren Cream have been reported. Results from acute toxicity studies do not indicate that any risk of acute intoxication is to be expected following a single dermal application of an overdose (application over a large area under conditions favourable to absorption) or inadvertent oral ingestion. Due to the very low local and systemic toxicity of azelaic acid intoxication is unlikely.

Contraindications

R52.1 – Chronic intractable pain
R52.2 – Other chronic pain
R52.9 – Unspecified pain

Special warnings and precautions for use

For external use only.

). In the event of accidental contact, the eyes, mouth and/or affected mucous membranes should be washed with large amounts of water. If eye irritation persists, patients should consult a physician. The hands should be washed after each application of Skinoren Cream.

Worsening of asthma in patients treated with azelaic acid has been reported rarely during post-marketing surveillance.

Skinoren contains a small amount of benzoic acid, which is mildly irritating to the skin, eyes and mucous membranes.

Skinoren also contains propylene glycol, which may cause skin irritation.

Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

Fertility, pregnancy and lactation

Pregnancy

There are no adequate and well-controlled studies of topically administered azelaic acid in pregnant women.

Animal studies do indicate the potential for effects with respect to pregnancy, embryo-fetal development, parturition or postnatal development.).

Caution should be exercised when prescribing azelaic acid to pregnant women.

Lactation

Infants must not come into contact with treated skin/breast.

It is not known if azelaic acid is passed into breast milk in vivo. Due to low percutaneous absorption and since azelaic acid is not concentrated in milk, the amount of azelaic acid reaching the infant via mother's milk is approximately 0.01%. This corresponds to less than 200 Âµg per day following administration of the maximum recommended dose of 5 g Skinoren 20% Cream twice daily. Caution should be exercised when Skinoren Cream is administered to a nursing mother.

Fertility

There are no data on the effect of Skinoren cream on human fertility.Preclinical safety data).

Effects on ability to drive and use machines

Skinoren Cream has no influence on the ability to drive and use machines.

Pharmacodynamic properties

Pharmacotherapeutic group: other anti-acne preparations for topical use.

ATC Code: D10AX03

The antimicrobial action and a direct influence on follicular hyperkeratosis are assumed to be the basis for the therapeutic efficacy of Skinoren in acne.

Clinically, a significant reduction of the colonization density of Propionibacterium acnes and a significant reduction of the fraction of free fatty acids in the skin surface lipids is observed.

In vitro and in vivo, azelaic acid inhibits the proliferation of keratinocytes and normalizes the disturbed terminal epidermal differentiation processes in acne. In the rabbit ear model, azelaic acid accelerates the comedolysis of tetradecane-induced comedones.

There is clinical experience for a continuous application time period of up to one year.

Pharmacokinetic properties

After dermal administration of the cream, azelaic acid penetrates into all layers of human skin. The penetration is more rapid into damaged skin than into intact skin. A total of 3.6% of the administered dose was absorbed percutaneously after a single topical administration of 1 g azelaic acid (5 g cream).

A portion of the azelaic acid which is absorbed through the skin is eliminated unchanged with the urine. The remaining portion is metabolized through beta- oxidation into short-chained dicarboxylic acids (C₇, C₅ carboxylic acids) which have likewise been found in the urine.